OUR PRODUCTS

RESPIRATORY NEWS

Sandoz launches generic version of Pulmicort Respules®

Princeton, New Jersey, July 28, 2015

Sandoz today announced the US market introduction of its budesonide inhalation suspension, a generic version of Pulmicort Respules® (budesonide) inhalation suspension 1 mg strength by AstraZeneca LP.

Sandoz launches Breathe Africa program to improve asthma diagnosis, treatment and patient outcomes in Zambia

Holzkirchen, Germany, July 24, 2015

Sandoz today announced the launch of Breathe Africa, a respiratory health program aimed at improving the diagnosis and treatment of asthma through sharing medical expertise and donating medicines.

Innovative respiratory inhaler AirFluSal® Forspiro® receives Alufoil Trophy 2015

April 16, 2015

AirFluSal® Forspiro®, an innovative respiratory inhaler from Sandoz, has won the coveted Alufoil Trophy 2015 in the Product Preservation category. The inhaler uses a specially designed alufoil blister strip, which was developed by Amcor Flexibles, that ensures a longer shelf life of the inhalation powder.

Sandoz launches innovative respiratory inhaler AirFluSal® Forspiro® in Portugal and Ireland

Holzkirchen, March 11, 2015

Sandoz today announces the launch of AirFluSal® Forspiro®, an innovative inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD), in Portugal and Ireland.

Sandoz receives approvals in Ireland and Czech Republic for innovative respiratory inhaler AirFluSal® Forspiro®

Holzkirchen, November 19, 2014

Sandoz announces today that the pharmaceutical regulatory authorities in Ireland and the Czech Republic have granted marketing authorizations for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

Sandoz receives approvals in Baltics for innovative respiratory inhaler AirFluSal® Forspiro®

Holzkirchen, November 4, 2014

Sandoz announces today that the pharmaceutical regulatory authorities in Estonia, Latvia and Lithuania have all granted marketing authorizations for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

Sandoz receives approval in Portugal for innovative respiratory inhaler AirFluSal® Forspiro®

Holzkirchen, October 9, 2014

Sandoz announces today that the Portuguese Health Authority (Infarmed) has granted marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

Sandoz receives first approval in Latin America for innovative respiratory inhaler Airflusal® Forspiro®

Holzkirchen, August 20, 2014

Sandoz announces today that the Mexican Health Authority (COFEPRIS) has granted Sandoz marketing authorization for Airflusal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

Sandoz launches Airflusal® Forspiro® in Sweden, further driving patient access to innovative new respiratory inhaler

June 23, 2014

Sandoz today announced the launch in Sweden of Airflusal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

GSK application for preliminary injunction withdrawn just before Cologne Court of appeals was to rule in the case

June 16, 2014

Pharmaceutical company GlaxoSmithKline has withdrawn its application for a preliminary injunction on German marketing and distribution of Sandoz’s innovative and cost-effective respiratory inhaler, AirFluSal® Forspiro®, shortly before the Cologne Court of Appeals was due to rule in the case.

Sandoz France launches generic Nasonex® nasal spray, the first generic nasal corticoid on the French market

June 2, 2014

Sandoz, the generic pharmaceuticals division of Novartis, today announces the launch in France of Mometasone Sandoz®, the first generic version of leading respiratory therapy Nasonex®. Mometasone Sandoz® is indicated for the treatment of conditions including allergic rhinitis.

Sandoz launches AirFluSal® Forspiro® in South Korea

May 14, 2014

Sandoz Korea announces that it is launching today AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

Court supports access to Sandoz’s innovative respiratory device in Norway

May 8, 2014

We are pleased that a court in Norway has denied GSK’s request to restrict access to Sandoz’s AirFluSal® Forspiro® in Norway.

Court supports access to Sandoz’s innovative respiratory device in Norway

Apr 2, 2014

Sandoz announces today that it is launching in Norway AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

South Korea approves AirFluSal® Forspiro®

Feb 28, 2014

Sandoz announced today it has received South Korean marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD, marking its first approval in Asia.

Belgium approves Sandoz’s AirFluSal® Forspiro®

Feb 12, 2014

Sandoz announced it has received marketing authorization in Belgium for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

Norway approves Sandoz’s AirFluSal® Forspiro®

Feb 10, 2014

Sandoz announced today it has received Norwegian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

Bulgaria approves Sandoz’s AirFluSal® Forspiro®

Feb 4, 2014

Sandoz announced today it has received Bulgarian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

Romania approves Sandoz’s AirFluSal® Forspiro®

Jan 29, 2014

Sandoz announced today it has received Romanian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

Sandoz launches AirFluSal ® Forspiro® in Denmark

Jan 20, 2014

Sandoz announces that it is launching in Denmark today AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

Hungary approves Sandoz’s AirFluSal® Forspiro®

Jan 16, 2014

Sandoz announced it has received marketing authorization in Hungary for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

Sweden approves Sandoz’s AirFluSal® Forspiro®

Jan 14, 2014

Sandoz announced today it has received Swedish marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

Germany approves Sandoz’s AirFluSal® Forspiro®

Jan 13, 2014

Sandoz announced today it has received German marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

Sandoz receives first approval for AirFluSal® Forspiro®

Dec 18, 2013

Sandoz announced today that it has received Danish marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).